Product logins

Find logins to all Clarivate products below.


Hospital-Treated Infections | TreatmentTrends | US | 2015

Hospital emergency departments (EDs) are sites where the majority of patients with serious, acute bacterial infections initially seek medical care. As such, these sites often represent the initial treatment setting, where patients receive the first dose of antibiotic(s) and are triaged for possible hospital admission or subsequent therapy in the outpatient setting. Therefore, EDs play an important role in initial treatment/brand selection. This report examines the current trends in management and antibiotic treatment of patients presenting to EDs with bacterial infections, and it examines their management and treatment through hospital inpatient and/or outpatient care following discharge. The report evaluates prescribing practices and guidelines in the ER, in the inpatient setting, and upon patient discharge.

Related Market Assessment Reports

Report
Muscular Dystrophy – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. The standard treatment for MD…
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
Report
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s…